GSK's Ambitious Move Weighs on FTSE 100

The FTSE 100 index dropped by 0.3% on Tuesday, primarily influenced by GSK's decision to acquire U.S.-based drug developer Nuvalent for $10.6 billion. The acquisition is part of GSK's strategy to enhance its lung cancer treatment portfolio. Meanwhile, the FTSE 250 saw a slight increase of 0.2%.

On Tuesday, the UK's premier stock index, the FTSE 100, witnessed a decline of 0.3%, closing at 10,341 points by 0810 GMT. The drop was predominantly due to a shift in GSK shares as the healthcare giant announced its acquisition of Nuvalent, a U.S. drug developer, for $10.6 billion.

GSK's strategic purchase aims to bolster its lung cancer treatment options, an area of significant growth and competition in the pharmaceutical sector. Investors reacted swiftly to the news, influencing the overall performance of the heavily weighted FTSE 100.

In contrast, the midcap FTSE 250 index experienced a slight uptick of 0.2%, showcasing resilience amid the larger index's decline.